BML-259, with the CAS number 267654-00-2, is a chemical compound that has garnered interest in the field of medicinal chemistry, particularly for its potential applications in drug discovery and development. It is characterized by its specific molecular structure, which includes various functional groups that contribute to its biological activity. BML-259 is often studied for its role as a selective inhibitor, potentially affecting specific biochemical pathways or targets within cells. The compound's solubility, stability, and reactivity are important characteristics that influence its efficacy and safety profile in biological systems. Additionally, its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion (ADME), are critical for understanding its behavior in vivo. Research on BML-259 may also explore its interactions with other molecules, which can provide insights into its mechanism of action and therapeutic potential. Overall, BML-259 represents a significant area of interest for researchers aiming to develop new therapeutic agents.

BML-259 (267654-00-2) is a potent inhibitor of Cdk5/p25 (IC50 = 64 nM) and Cdk2 (IC50 = 98nM).1

BML-259

267654-00-2: BML-259, with the CAS number 267654-00-2, is a chemical compound that has garnered interest in the field of medicinal chemistry, particularly for its potential applications in drug discovery and development. It is characterized by its specific molecular structure, which includes various functional groups that contribute to its biological activity. BML-259 is often studied for its role as a selective inhibitor, potentially affecting specific biochemical pathways or targets within cells. The compound's solubility, stability, and reactivity are important characteristics that influence its efficacy and safety profile in biological systems. Additionally, its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion (ADME), are critical for understanding its behavior in vivo. Research on BML-259 may also explore its interactions with other molecules, which can provide insights into its mechanism of action and therapeutic potential. Overall, BML-259 represents a significant area of interest for researchers aiming to develop new therapeutic agents.

<p>BML-259 inhibits CDK5/CDK2 (IC50: 64/98 nM) for cancer and neurodegeneration research.</p>

CAS 267654-00-2

BML-259

BML-259

Ref: 54-BUP10666

BML-259

Ref: TM-T36964